GET DAILY SIGNALSInMed Pharmaceuticals (INM) Reports Q1 Fiscal 2027 Results With Focus on Cash and Merger
Key Takeaways
- InMed Pharmaceuticals (INM) reported a net loss of approximately $2.33 million for the first quarter of fiscal 2027, ended September 30, 2026, compared with roughly $1.73 million in the prior-year period.
- The company ended the quarter with about $1.09 million in cash and cash equivalents, down from approximately $2.19 million at June 30, 2026.
- Management reiterated that its cash runway is expected to fund planned operating expenses only into mid-November 2026, underscoring the importance of the pending transaction.
- The proposed merger with Mentari Therapeutics, Inc. advanced, with shareholder meetings scheduled for November 4, 2026 to approve the deal.
- Research and development (R&D) expenses declined year over year, while general and administrative (G&A) expenses rose, reflecting reduced pipeline activity ahead of the merger.
- The company submitted a Nasdaq compliance plan after shareholders' equity fell below the exchange's minimum requirement, with a deadline of March 15, 2027 to regain compliance.
Earnings Context and Why It Matters
InMed Pharmaceuticals (INM) is a clinical-stage pharmaceutical company focused on small molecule drug candidates targeting the CB1 and CB2 receptors, with programs in Alzheimer's disease, ocular indications, and dermatology. Its quarterly results matter less for top-line revenue and more for cash position, pipeline progress, and corporate strategy. The company's fiscal year ends June 30, making the quarter ended September 30, 2026 the first quarter of fiscal 2027. With a shrinking cash balance and a pending merger with Mentari Therapeutics, this report serves as a critical checkpoint on the company's ability to fund operations and complete its strategic transformation. I checked a few peer comparisons using Tickeron’s AI Screener to put the numbers in context.
Reported Results
For the first quarter of fiscal 2027, ended September 30, 2026, InMed reported a net loss including discontinued operations of approximately $2.33 million, compared with roughly $1.73 million in the same period a year earlier. The net loss from continuing operations was about $2.00 million, versus approximately $1.83 million in the prior-year quarter.
Research and development (R&D) expenses declined to roughly $206,000 from about $575,500 a year ago, reflecting reduced operational activity tied to the proposed merger. In contrast, general and administrative (G&A) expenses increased to approximately $1.80 million from about $1.24 million in the prior-year period.
Cash and cash equivalents stood at approximately $1.09 million as of September 30, 2026, down from about $2.19 million at June 30, 2026. Management indicated that, based on current forecasts, available cash is expected to support planned operating expenses and capital expenditures into mid-November 2026, depending on spending levels, timing, and the completion of the proposed merger. One thing that stands out here is how quickly the cash position has tightened.
Market Reaction and Investor Sentiment
Investor attention around this earnings event has centered less on the reported loss and more on the company's corporate strategy. The pending merger with Mentari Therapeutics and the associated financing remain the dominant drivers of sentiment. With a cash runway extending only into mid-November 2026, shareholders are closely watching whether the transaction closes on schedule, as its completion is expected to address both the company's funding needs and its Nasdaq listing compliance concerns. The narrow runway introduces execution risk, and any delay in the merger or related financing could weigh on sentiment. From what I see, this remains the key variable to track.
Forward Outlook and Key Factors to Monitor
Looking ahead, the single most important catalyst is the completion of the proposed merger with Mentari Therapeutics. If approved, the combined company is expected to operate under the Mentari Therapeutics name and seek to trade on the Nasdaq Capital Market under a new ticker, subject to exchange approval. Mentari has announced private financing expected to total roughly $490 million, which the companies believe would support operations into 2029 and fund Phase 2a data readouts for two lead PACAP-targeting programs.
Investors should also monitor Nasdaq compliance. The company received notice that its shareholders' equity of approximately $1.08 million as of the fiscal year ended June 30, 2026 fell below the exchange's $2.5 million minimum. InMed submitted a compliance plan on October 30, 2026, and Nasdaq accepted it, giving the company until March 15, 2027 to regain compliance.
On the pipeline front, InMed completed a pre-IND meeting with the U.S. Food and Drug Administration (FDA) regarding INM-901 for Alzheimer's disease and continues to pursue divestiture, licensing, and other strategic opportunities for INM-901, INM-089, and INM-755. The proposed merger includes a contingent value right structure intended to allow eligible InMed shareholders to participate in potential future value from these assets, though any associated transactions and payments remain uncertain. I’m watching this closely as the deal timeline unfolds.
Exploring AI Tools in My Research
I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. The platform helped me quickly filter for similar small-cap biopharma names and review recent signals. It is a useful way to cross-check fundamentals and technical patterns when following names like INM that are in transition.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for INM turns positive, indicating new upward trend
INM saw its Momentum Indicator move above the 0 level on October 19, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 93 similar instances where the indicator turned positive. In 85 of the 93 cases, the stock moved higher in the following days. The odds of a move higher are at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
INM moved above its 50-day moving average on October 23, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for INM crossed bullishly above the 50-day moving average on October 27, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 86%.
Following a +7.36% 3-day Advance, the price is estimated to grow further. Considering data from situations where INM advanced for three days, in 150 of 184 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
INM broke above its upper Bollinger Band on October 23, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. INM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 52 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: INM's P/B Ratio (70.779) is slightly higher than the industry average of (7.659). P/E Ratio (-4.439) is within average values for comparable stocks, (0.330). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (0.891) is also within normal values, averaging (181.047).
The Tickeron PE Growth Rating for this company is 68 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry PharmaceuticalsGeneric
Advertisement